EE05661B1 - Formoterooli ja budesoniidi sisaldava ravimkoostise kasutamine astma „gedate seisundite v„ltimiseks v?i raviks - Google Patents

Formoterooli ja budesoniidi sisaldava ravimkoostise kasutamine astma „gedate seisundite v„ltimiseks v?i raviks

Info

Publication number
EE05661B1
EE05661B1 EEP200000740A EEP200000740A EE05661B1 EE 05661 B1 EE05661 B1 EE 05661B1 EE P200000740 A EEP200000740 A EE P200000740A EE P200000740 A EEP200000740 A EE P200000740A EE 05661 B1 EE05661 B1 EE 05661B1
Authority
EE
Estonia
Prior art keywords
formoterol
asthma
prevention
treatment
related conditions
Prior art date
Application number
EEP200000740A
Other languages
English (en)
Estonian (et)
Inventor
Ekstr�m Tommy
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20411658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05661(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200000740A publication Critical patent/EE200000740A/xx
Publication of EE05661B1 publication Critical patent/EE05661B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EEP200000740A 1998-06-11 1999-06-10 Formoterooli ja budesoniidi sisaldava ravimkoostise kasutamine astma „gedate seisundite v„ltimiseks v?i raviks EE05661B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802073A SE9802073D0 (sv) 1998-06-11 1998-06-11 New use
PCT/SE1999/001031 WO1999064014A1 (en) 1998-06-11 1999-06-10 Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma

Publications (2)

Publication Number Publication Date
EE200000740A EE200000740A (et) 2002-04-15
EE05661B1 true EE05661B1 (et) 2013-06-17

Family

ID=20411658

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000740A EE05661B1 (et) 1998-06-11 1999-06-10 Formoterooli ja budesoniidi sisaldava ravimkoostise kasutamine astma „gedate seisundite v„ltimiseks v?i raviks

Country Status (35)

Country Link
US (2) US20010049396A1 (id)
EP (3) EP1085877B1 (id)
JP (1) JP2002517450A (id)
KR (1) KR20010052721A (id)
CN (1) CN100389771C (id)
AR (1) AR018410A1 (id)
AT (1) ATE389409T1 (id)
AU (1) AU771715B2 (id)
BR (1) BR9911073A (id)
CA (1) CA2334411C (id)
CY (1) CY1110376T1 (id)
CZ (1) CZ300874B6 (id)
DE (1) DE69938390T2 (id)
DK (1) DK1085877T3 (id)
EE (1) EE05661B1 (id)
ES (1) ES2302384T3 (id)
HK (1) HK1035145A1 (id)
HU (1) HUP0103108A3 (id)
ID (1) ID27937A (id)
IL (2) IL139921A0 (id)
IS (1) IS5752A (id)
MY (1) MY129281A (id)
NO (3) NO20006253L (id)
NZ (1) NZ536279A (id)
PL (1) PL344665A1 (id)
PT (1) PT1085877E (id)
RU (1) RU2222332C2 (id)
SA (1) SA99200234B1 (id)
SE (1) SE9802073D0 (id)
SK (1) SK286252B6 (id)
TR (1) TR200003666T2 (id)
TW (1) TWI252756B (id)
UA (1) UA87956C2 (id)
WO (1) WO1999064014A1 (id)
ZA (1) ZA200006943B (id)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
BR0015884A (pt) 2000-05-22 2003-07-08 Chiesi Farma Spa Formulações de soluções farmacêuticas estáveis para inaladores de dose medida pressurizados
SI1273292T1 (en) 2001-07-02 2004-12-31 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
EP1992335A1 (en) * 2001-11-01 2008-11-19 Nektar Therapeutics Spray drying methods and compositions thereof
FI20020126A0 (fi) * 2002-01-23 2002-01-23 Orion Corp Koostumuksia pulmonaaliseen antoon
SE0200312D0 (sv) * 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
JP4744876B2 (ja) * 2002-08-21 2011-08-10 ノートン・ヘルスケアー リミテッド 乾燥粉末吸入組成物の製造方法
GB0219511D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
GB0219512D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
US20070098644A1 (en) * 2005-10-31 2007-05-03 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
EP2120875B1 (en) 2007-02-11 2018-07-11 Map Pharmaceuticals Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
AU2008217586A1 (en) 2007-02-19 2008-08-28 Cipla Limited Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
EP1982709A1 (en) 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
LT2435025T (lt) 2009-05-29 2016-09-26 Pearl Therapeutics, Inc. Veikliosios medžiagos tiekimas per kvėpavimo takus
PT2538922T (pt) * 2010-02-25 2016-07-11 Andi-Ventis Ltd Formulação de composições para o tratamento de doenças inflamatórias
NZ605920A (en) * 2010-07-16 2015-01-30 Cipla Ltd Pharmaceutical compositions comprising r (+) budesonide and one or more bronchodilators
CN105640925B (zh) 2010-08-30 2019-08-16 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
EP2448571B1 (en) 2010-08-30 2013-06-12 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
CN102416179B (zh) 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
EP2621488B1 (en) 2010-09-29 2018-11-07 Pulmatrix Operating Company, Inc. Cationic dry powders
AU2011308865B2 (en) 2010-09-29 2017-01-05 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
NZ629722A (en) 2012-02-29 2017-03-31 Pulmatrix Operating Co Inc Inhalable dry powders
RU2504382C1 (ru) * 2012-06-13 2014-01-20 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
CN105324106A (zh) 2013-04-01 2016-02-10 普马特里克斯营业公司 噻托铵干粉
ITMI20130571A1 (it) 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
WO2017108917A1 (en) * 2015-12-22 2017-06-29 Astrazeneca Ab Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease
IT202000006442A1 (it) 2020-03-27 2021-09-27 Genetic S P A Budesonide 21-phosphate salts and pharmaceutical compositions containing the same

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203401A (en) 1979-01-29 1980-05-20 General Motors Corporation Evaporative emissions canister
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
GB2235626B (en) 1989-09-08 1994-02-09 Glaxo Group Ltd Inhalation medicaments for treating respiratory disorders
US5250286A (en) * 1990-05-07 1993-10-05 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline
PL164294B1 (pl) 1990-12-20 1994-07-29 Inst Farmaceutyczny Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5119791A (en) 1991-06-07 1992-06-09 General Motors Corporation Vapor storage canister with liquid trap
US5444521A (en) 1991-07-15 1995-08-22 Canon Kabushiki Kaisha Image fixing device capable of controlling heating overshoot
NZ246050A (en) * 1991-12-18 1995-12-21 Astra Ab Formerly Aktiebolaget Medicament containing formoterol and budesonide for treatment of respiratory disorders
EP1086697A2 (en) 1991-12-18 2001-03-28 AstraZeneca AB New combination of formoterol and budesonide
US5408977A (en) 1993-08-23 1995-04-25 Walbro Corporation Fuel tank with carbon canister and shut-off valve
RU2170082C2 (ru) 1993-10-01 2001-07-10 Астра Актиеболаг Способ обработки лекарственного средства, устройство для формирования лекарственного средства и лекарственное средство
SE9404080L (sv) * 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5511957A (en) 1994-09-27 1996-04-30 Walbro Corporation High capacity fuel pump and filter combination
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
GB9519692D0 (en) * 1995-09-27 1995-11-29 Quillin Helen Atomising nozzle
CA2238298A1 (en) 1995-11-24 1997-06-19 Luca Francesco Raveglia Quinoline derivatives
US5651349A (en) 1995-12-11 1997-07-29 Chrysler Corporation Purge system flow monitor and method
SE9603669D0 (sv) * 1996-10-08 1996-10-08 Astra Ab New combination
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
PL337722A1 (en) 1997-06-27 2000-08-28 Astra Ab Novel combination antiasthmatic drugs
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US5957114A (en) 1998-07-17 1999-09-28 Ford Motor Company Evaporative emission canister for an automotive vehicle
US5924410A (en) 1998-07-20 1999-07-20 Ford Motor Company Evaporative emission canister for an automotive vehicle
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6227862B1 (en) * 1999-02-12 2001-05-08 Advanced Drivers Education Products And Training, Inc. Driver training system
EP1031725B1 (en) 1999-02-26 2004-12-29 Walbro Corporation Vehicle fuel system
SE9900834D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination
US6237574B1 (en) 1999-04-20 2001-05-29 Ford Motor Company Evaporative emission canister for an automotive vehicle
US6136075A (en) 1999-05-03 2000-10-24 Westvaco Corporation Automotive evaporative emissions canister adsorptive restraint system
JP3646217B2 (ja) 1999-07-08 2005-05-11 愛三工業株式会社 キャニスタモジュール
US6374811B1 (en) 2000-10-04 2002-04-23 Ford Global Technologies, Inc. System and method for minimizing fuel evaporative emissions from an internal combustion engine

Also Published As

Publication number Publication date
US20010049396A1 (en) 2001-12-06
CA2334411C (en) 2008-07-15
NO20140823L (no) 2001-02-12
SK18882000A3 (sk) 2001-07-10
NO20006253D0 (no) 2000-12-08
NZ536279A (en) 2007-01-26
SK286252B6 (sk) 2008-06-06
DE69938390D1 (de) 2008-04-30
ID27937A (id) 2001-05-03
PT1085877E (pt) 2008-05-13
MY129281A (en) 2007-03-30
IL139921A0 (en) 2002-02-10
ATE389409T1 (de) 2008-04-15
US20040063676A1 (en) 2004-04-01
UA87956C2 (uk) 2009-09-10
WO1999064014A1 (en) 1999-12-16
US9295644B2 (en) 2016-03-29
CZ300874B6 (cs) 2009-09-02
AR018410A1 (es) 2001-11-14
CY1110376T1 (el) 2015-04-29
HUP0103108A2 (hu) 2002-05-29
EP2266574A1 (en) 2010-12-29
DE69938390T2 (de) 2009-03-05
ES2302384T3 (es) 2008-07-01
HK1035145A1 (en) 2001-11-16
SA99200234B1 (ar) 2007-03-10
JP2002517450A (ja) 2002-06-18
CA2334411A1 (en) 1999-12-16
EE200000740A (et) 2002-04-15
CN100389771C (zh) 2008-05-28
AU4671099A (en) 1999-12-30
CZ20004593A3 (cs) 2001-04-11
DK1085877T3 (da) 2008-06-09
EP1085877A1 (en) 2001-03-28
IS5752A (is) 2000-12-05
PL344665A1 (en) 2001-11-19
NO20130269L (no) 2001-02-12
EP1085877B1 (en) 2008-03-19
RU2222332C2 (ru) 2004-01-27
TR200003666T2 (tr) 2001-06-21
HUP0103108A3 (en) 2002-11-28
AU771715B2 (en) 2004-04-01
CN1305380A (zh) 2001-07-25
NO20006253L (no) 2001-02-12
IL139921A (en) 2006-10-05
EP1316311A1 (en) 2003-06-04
ZA200006943B (en) 2002-02-27
SE9802073D0 (sv) 1998-06-11
TWI252756B (en) 2006-04-11
BR9911073A (pt) 2001-02-20
KR20010052721A (ko) 2001-06-25

Similar Documents

Publication Publication Date Title
EE05661B1 (et) Formoterooli ja budesoniidi sisaldava ravimkoostise kasutamine astma „gedate seisundite v„ltimiseks v?i raviks
FI971969A0 (fi) Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
BR9507656A (pt) Composto utilização de um composto composição farmacéutica e processos para o tratamento de um paciente que sofre de dor e para a preparação de um composto
PT1181027E (pt) Composicao dietetica ou farmaceutica para utilizacao na prevencao ou tratamento de hiperoxaluria
EE200000145A (et) Budesoniidi ja formoterooli uus kasutamine
HUP0102899A3 (en) Process for preparation of compositions for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
BR9706822A (pt) Composição kit processo para tratamento de um distúrbio respiratório e utilização da composição do kit de formoterol de um sal ou solvato farmaceuticamente aceitável do mesmo e de budesonida
DE69519672D1 (de) Synergistische tensidzusammensetzungen und konzentrate davon zur feuerbekämpfung
LV11865A (lv) Kompozicijas un panemieni tuklo sunu iekaisumu arstesanai
EE9900036A (et) Uued ühendid ja kompositsioonid trüptaasi aktiivsusega seotud haiguste raviks
IT1302365B1 (it) Uso di carnitine e resveratrolo per produrre una composizione per laprevenzione o il trattamento terapeutico di alterazioni cerebrali
HUP9903166A3 (en) Medicinal compositions for the prophylaxis or treatment of arteriosclerosis
IT1289581B1 (it) Miscela,composizione per la protezione delle piante contenente la miscela e suo impiego
GB2311940B (en) Pharmaceutical compositions for the treatment of rhinitis
BR9508110A (pt) Derivado de triterpeno e composição médica
EE04043B1 (et) H+,K+-ATPaasi inhibiitori ja glükokortikoidide kasutamine ravimvormi valmistamiseks
FI962685A0 (fi) 2,3-diaryyli-1-bentsopyraanijohdannaisten käyttö lääkkeen valmistamiseksi luukadon ja osteoporoosin hoitamiseksi ja estämiseksi
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
FI961380A (fi) Koostumuksia virusten aiheuttamien kasvainten ehkäisemiseksi ja hoitamiseksi
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
AP9700928A0 (en) Pharmaceutical compositions for the prevention or treatment of retrovirus infections
AU3061199A (en) Skin treatment compositions and the use thereof
SI1085877T1 (sl) Uporaba sestavka, ki obsega formoterol in budezonid, za preprečevanje ali zdravljenje akutnega stanja